Efficacy of different administration methods of vonoprazan for gastroesophageal reflux disease: a retrospective cohort study
Diseases of the Esophagus · 01.09.2025 · 38 (5)
DOI: 10.1093/dote/doaf092 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diseases of the Esophagus, online erschienen am 29.10.2025. Verfasst von Qianqian Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Pyrroles, Sulfonamides, Proton Pump Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Vonoprazan, a potassium competitive acid blocker (P-CAB), shows promise for gastroesophageal reflux disease (GERD). On-demand therapy may reduce costs and drug exposure. This study aimed to compare the efficacy of on-demand versus continuous vonoprazan treatment in the initial management of mild GERD. This observational cohort study enrolled patients with non-erosive reflux disease (NERD) and mild reflux esophagitis (LA grade A/B). Patients were allocated to either on-demand or continuous vonoprazan (20 mg/day) treatment for 4 weeks. Primary outcomes were changes in Gastroesophageal Reflux Disease Questionnaire (GerdQ) and Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) scores. Secondary outcomes included treatment satisfaction, complete mucosal healing rate, and 24-week relapse rate. The GerdQ score and GERD-HRQL score of the on-demand treatment group decreased significantly after initial treatment compared with the previous one, with statistical significance (P < 0.001). Moreover, there were no significant differences in GerdQ and GERD-HRQL scores between the two groups after the treatment (P = 0.363, P = 0.037; the significance level was P < 0.025). Satisfaction (75.9% vs. 74.3%), complete mucosal healing rates (61.8% vs. 38.8%), and relapse rates (10.2% vs. 8.9%) were comparable in the on-demand and continuous treatment groups. Age (OR = 1.08, 95% CI: 1.05–1.11, P < 0.001) and alcohol consumption (OR = 4.31, 95% CI: 1.06–17.41, P = 0.04) were influential factors for symptom burden improvement, and treatment allocation (P = 0.069) had no significant effect on symptom burden improvement. Age (OR = 0.94, 95% CI: 0.91–0.96, P < 0.001) and pre-treatment Los Angeles grade B (OR = 3.28, 95% CI: 1.46–7.34, P = 0.004) were predictors of improved quality of life. This study found on-demand vonoprazan demonstrates comparable efficacy to continuous therapy for mild GERD, offering a cost-effective strategy with minimized drug accumulation risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- Department of Gastroenterology, Medical Key Laboratory for Diagnosis and Treatment of Colorectal Cancer in Henan Province, Zhengzhou, China.
- Department of Gastroenterology, Zhengzhou Key Laboratory for Diagnosis, Treatment and Research of Colorectal Cancer, Zhengzhou, China.
Zitieren
APA
Wu, Q., Li, D., Li, L., Chen, S., Xu, W., Zhang, J., Wu, H., Chu, F., Li, K., & Wang, L. (2025). Efficacy of different administration methods of vonoprazan for gastroesophageal reflux disease: a retrospective cohort study. Diseases of the Esophagus, 38(5). https://doi.org/10.1093/dote/doaf092
Vancouver
Wu Q, Li D, Li L, Chen S, Xu W, Zhang J, et al. Efficacy of different administration methods of vonoprazan for gastroesophageal reflux disease: a retrospective cohort study. Diseases of the Esophagus. 2025;38(5). doi:10.1093/dote/doaf092
BibTeX
@article{Wu2025,
author = {Wu, Qianqian and Li, Di and Li, Lu and Chen, Shuang and Xu, Wenting and Zhang, Jiale and Wu, Huili and Chu, Feifei and Li, Kunkun and Wang, Lihong},
title = {Efficacy of different administration methods of vonoprazan for gastroesophageal reflux disease: a retrospective cohort study},
journal = {Diseases of the Esophagus},
year = {2025},
volume = {38},
number = {5},
doi = {10.1093/dote/doaf092}
}
EUVIMED